Format

Send to

Choose Destination
See comment in PubMed Commons below
Gan To Kagaku Ryoho. 2012 Nov;39(12):1779-81.

[Evaluation of quality of life and immune function in cancer patients receiving combined immunotherapy and oral administration of lentinula edodes mycelia extract].

[Article in Japanese]

Author information

1
Tokyo Women's Medical University, Tokyo, Japan.

Abstract

Lentinula edodes mycelia extract(LEM) may mitigate the immunosuppression caused by regulatory T cells(Tregs), and it is therefore expected that LEM will be useful with cancer immunotherapy. In this study, we evaluated the quality of life (QOL) and immune function in cancer patients receiving a combination of immunotherapy and oral administration of LEM.

METHODS:

Ten patients who had received cancer immunotherapy were enrolled. They received cancer immunotherapy alone for the first 4 weeks, and were then administered LEM (1,800 mg/day) with cancer immunotherapy for the next 4 weeks. QOL scores and immune parameters were evaluated at weeks 0, 4, and 8.

RESULTS:

The total score for QOL was improved during the period with LEM administration compared to the period with immunotherapy alone. Interferon (IFN)-γ secretion from peripheral blood cells was increased during the period with LEM administration. The change in IFN-γ secretion in the LEM administration period possibly correlated with changes in the Treg population.

CONCLUSION:

Oral administration of LEM may improve QOL and immunity in patients receiving cancer immunotherapy.

PMID:
23267884
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Sunmedia PierOnline
    Loading ...
    Support Center